References
1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is
polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct
10;17(1):230. doi: 10.1186/s12877-017-0621-2. PMID: 29017448; PMCID:
PMC5635569.
2. Medication Safety in Polypharmacy. Geneva: World Health Organization;
2019 (WHO/UHC/SDS/2019.11). Licence: CC BY-NC-SA 3.0 IG. URL:
https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11 Accessed:
01/07/2022
3. Rawle MJ, Richards M, Davis D, Kuh D. The prevalence and determinants
of polypharmacy at age 69: a British birth cohort study. BMC Geriatr.
2018 May 16;18(1):118. doi: 10.1186/s12877-018-0795-2. PMID: 29769020;
PMCID: PMC5956732.
4. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor
for adverse drug reactions in geriatric nursing home residents. Am J
Geriatr Pharmacother. 2006 Mar;4(1):36-41. doi:
10.1016/j.amjopharm.2006.03.002. PMID: 16730619.
5. Rawle MJ, Cooper R, Kuh D, Richards M. Associations Between
Polypharmacy and Cognitive and Physical Capability: A British Birth
Cohort Study. J Am Geriatr Soc. 2018 May;66(5):916-923. doi:
10.1111/jgs.15317. Epub 2018 Mar 24. PMID: 29574684; PMCID: PMC6001617.
6. Spaniolas, Konstantinos MD; Cheng, Julius D. MD, MPH; Gestring, Mark
L. MD; Sangosanya, Ayodele MD; Stassen, Nicole A. MD; Bankey, Paul E. MD
Ground Level Falls Are Associated With Significant Mortality in Elderly
Patients, The Journal of Trauma: Injury, Infection, and Critical Care:
October 2010 - Volume 69 - Issue 4 - p 821-825. doi:
10.1097/TA.0b013e3181efc6c6
7. Cartagena LJ, Kang A, Munnangi S, et al. Risk factors associated with
in-hospital mortality in elderly patients admitted to a regional trauma
center after sustaining a fall. Aging Clin Exp Res. 2017
Jun;29(3):427-433. doi: 10.1007/s40520-016-0579-5. Epub 2016 May 3.
PMID: 27142683.
8. Fadare JO, Obimakinde AM, Aina FO, Araromi EJ, et al.
Anti-Cholinergic Drug Burden Among Ambulatory Elderly Patients in a
Nigerian Tertiary Healthcare Facility. Front Pharmacol. 2021 Jan
29;12:580152. doi: 10.3389/fphar.2021.580152. PMID: 33584317; PMCID:
PMC7878669.
9. Tan MP, Tan GJ, Mat S, Luben RN, Wareham NJ, Khaw KT, Myint PK. Use
of Medications with Anticholinergic Properties and the Long-Term Risk of
Hospitalization for Falls and Fractures in the EPIC-Norfolk Longitudinal
Cohort Study. Drugs Aging. 2020 Feb;37(2):105-114. doi:
10.1007/s40266-019-00731-3. PMID: 31808140; PMCID: PMC7115837.
10. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term
anticholinergic use and the aging brain. Alzheimers Dement. 2013
Jul;9(4):377-85. doi: 10.1016/j.jalz.2012.02.005. Epub 2012 Nov 22.
PMID: 23183138; PMCID: PMC3674201.
11. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A
systematic review of amnestic and non-amnestic mild cognitive impairment
induced by anticholinergic, antihistamine, GABAergic and opioid drugs.
Drugs Aging. 2012 Aug 1;29(8):639-58. doi: 10.1007/BF03262280. PMID:
22812538.
12. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint
PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M,
Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and
risk of dementia: case-control study. BMJ. 2018 Apr 25;361:k1315. doi:
10.1136/bmj.k1315. Erratum in: BMJ. 2019 Oct 31;367:l6213. PMID:
29695481; PMCID: PMC5915701.
13. Onder G, Liperoti R, Fialova D, et al. Polypharmacy in nursing home
in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med
Sci. 2012 Jun;67(6):698-704. doi: 10.1093/gerona/glr233. Epub 2012 Jan
4. PMID: 22219520.
14. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association
between polypharmacy and death: A systematic review and meta-analysis. J
Am Pharm Assoc (2003). 2017 Nov-Dec;57(6):729-738.e10. doi:
10.1016/j.japh.2017.06.002. Epub 2017 Aug 5. PMID: 28784299.
15. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication
use and cognitive impairment in the older population: the medical
research council cognitive function and ageing study. J Am Geriatr Soc.
2011 Aug;59(8):1477-83. doi: 10.1111/j.1532-5415.2011.03491.x. Epub 2011
Jun 24. PMID: 21707557.
16. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain
Barrier: From Physiology to Disease and Back. Physiol Rev. 2019 Jan
1;99(1):21-78. doi: 10.1152/physrev.00050.2017. PMID: 30280653; PMCID:
PMC6335099.
17. Hopewell S, Copsey B, Nicolson P, Adedire B, Boniface G, Lamb S.
Multifactorial interventions for preventing falls in older people living
in the community: a systematic review and meta-analysis of 41 trials and
almost 20 000 participants. Br J Sports Med. 2020 Nov;54(22):1340-1350.
doi: 10.1136/bjsports-2019-100732. Epub 2019 Aug 21. PMID: 31434659;
PMCID: PMC7606575.
18. Soundararajan, K., & Balchandra, P. (2021). Staff Awareness of
Anti-Cholinergic Burden (ACB) - A Qualitative Cross-Sectional Study in a
Tertiary Care Hospital. Cureus , 13 (3), e14141.
https://doi.org/10.7759/cureus.14141
19. Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C,
Lutters M. Quality of anticholinergic burden scales and their impact on
clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021
Feb;77(2):147-162. doi: 10.1007/s00228-020-02994-x. Epub 2020 Oct 3.
PMID: 33011824; PMCID: PMC7803697.
20. NICE. Falls: assessment and prevention of falls in older people.
(CG161). London: NICE, 2013. URL: http://www.nice.org.uk/guidance/cg161
(assessed 01/07/2022)